TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07565428: Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Rol

Sponsor: Minerva Neurosciences · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 380 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$17,630,720

Rescue Site Savings

+$11,625,256

Unlock Full NCT07565428 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07565428 Rescue Dossier →